You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKesson
AstraZeneca
Mallinckrodt
Harvard Business School
Dow
Colorcon

Last Updated: April 1, 2020

DrugPatentWatch Database Preview

Litigation Details for Par Pharmaceutical, Inc. v. TWi PHARMACEUTICALS, INC. (D. Maryland )


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in Par Pharmaceutical, Inc. v. TWi PHARMACEUTICALS, INC.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for Par Pharmaceutical, Inc. v. TWi PHARMACEUTICALS, INC. (D. Maryland )

Date Filed Document No. Description Snippet Link To Document
2013-07-17 140 generic Megace ES would infringe U.S. Patent 7,101,576 (“the ‘576 patent”). TWi has filed a motion for summary…TWi argues that U.S. Patent 5,399,363 (the ‘363 patent) anticipated the ‘576 patent. Par has cross moved…‘363 patent does not anticipate the ‘576 patent for a variety of reasons. First, the ‘363 patent appears…Alkermes’s already patented “NanoCrystal” technology), the inventors of the ‘576 patent discovered, “unexpectedly…inventors filed for patent protection for this new formulation, which was granted by the Patent Office in 2006 External link to document
2014-02-21 212 prosecution of the U.S. Patent No. 5,145,684 (“the ‘684 patent”), the patent originally disclosing nanoparticles…alleging infringement of U.S. Patent 7,101,576 (“the ‘576 patent”). The patent relates to Par’s Megace ES…the claims of the ‘576 patent are enabled, or whether the patent claims patentable subject matter. …claims of the ‘576 patent, leaving before this court only TWi’s defense that the ‘576 patent is invalid and…Alkermes’s already patented “NanoCrystal” technology), the inventors of the ‘576 patent discovered, “surprisingly External link to document
2014-08-12 257 alleging infringement of U.S. Patent 7,101,576 (“the ‘576 patent”). The patent relates to Par’s Megace ES… would infringe the asserted claims of the ‘576 patent, a five-day bench trial was held in October 2013…merits. The court ultimately concluded the ‘576 patent was invalid as obvious and issued its judgment …Circuit case law when deciding Rule 62(c) motions in patent cases. See, e.g., ePlus Inc. v. Lawson Software…the Federal Circuit may ultimately decide Par’s patent is valid. The cases on which TWi relies External link to document
2015-03-09 279 ”) alleging infringement of U.S. Patent 7,101,576 (“the ‘576 patent”). Following a bench trial in October…February 21, 2014 ultimately concluding the ‘576 patent was invalid as obvious. Par filed a notice of appeal…vacate the district court’s judgment that the ‘576 patent is obvious, and remand for further analysis…. 1:11-cv-02466-CCB Patent District Court, D. Maryland External link to document
2015-07-28 304 ”) alleging infringement of U.S. Patent No. 7,101,576 (“‘576 patent”). 1 After a five-day bench trial…the ‘576 patent also are invalid for lack of enablement. For a claim to be enabled, a patent’s specification…successfully tested for the purposes of the ‘576 patent. (See ‘576 patent tbl. 11.) Additionally, the upper end… the ‘576 patent teaches how to make the range of nanoparticle sizes claimed in the patent. (See Trial… issued a memorandum concluding that “the ‘576 patent was obvious, and thus invalid.” (Post-Tr. Mem. External link to document
2015-07-30 311 ”) alleging infringement of U.S. Patent 7,101,576 (“the ‘576 patent”). After a bench trial, the court…ruling issued on February 21, 2014 that the ‘576 patent was invalid as obvious. On appeal, the Federal…a ruling issued on July 28, 2015 that the ‘576 patent was (again) invalid as obvious, and that it was…one hand, the court has concluded that the ‘576 patent is invalid on an additional, independent basis.…. 1:11-cv-02466-CCB Patent District Court, D. Maryland External link to document
2016-09-27 351 Par acquired U.S. Patent No. 7,101,576 (“the ‘576 patent”) in 2006.2 The patent relates to Par’s Megace…with HIV and AIDS. After Par acquired the ‘576 patent, TWi filed an ANDA seeking FDA authorization to… the Hatch-Waxman Act), asserted that the ‘576 patent “is invalid or will not be infringed by the manufacture…product on the ground that it infringed the ‘576 patent. After a five-day bench trial, the court…court ruled on February 21, 2014, that the ‘576 patent was invalid as obvious. (Memorandum & Order, External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
AstraZeneca
Dow
Colorcon
Moodys
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.